Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Shoso Munemasa is active.

Publication


Featured researches published by Shoso Munemasa.


British Journal of Haematology | 2007

Connective tissue growth factor is an indicator of bone involvement in multiple myeloma, but matrix metalloproteinase-9 is not.

Shoso Munemasa; Akira Sakai; Yoshiaki Kuroda; Yoshiko Okikawa; Yuta Katayama; Hideki Asaoku; Tadahiko Kubo; Yoshitaka Miyakawa; Masahiro Serikawa; Tamito Sasaki; Akiro Kimura

Bone disease (BD) in multiple myeloma (MM) is because of the activation of osteoclasts and impairment of osteoblast differentiation. Connective tissue growth factor (CTGF) is known to participate in the differentiation of mesenchymal stem cells to committed osteoprogenitor cells. We analysed the concentration of circulating CTGF in 35 MM patients and 22 malignant lymphoma (ML) patients and 14 normal individuals. CTGF is protease‐sensitive and thus is found as both an N‐terminal half fragment (N‐half CTGF) and whole (W‐CTGF). Serum levels of W‐CTGF and N‐half CTGF + W‐CTGF were determined by separate sandwich enzyme‐linked immunosorbent assays. The level of W‐CTGF was significantly lower (P < 0·005) in MM patients compared with ML patients and normal individuals, while N‐half + W‐CTGF was similar in all groups. Furthermore, W‐CTGF was significantly lower in MM patients with BD compared with those without BD (P < 0·005) and this was independent of previous treatment. Matrix metalloproteinase (MMP)‐9 is produced by myeloma cells and is thought to be related to BD in MM. However, MMP‐9 does not cleave CTGF and serum MMP‐9 level was not related to BD in MM. Thus, CTGF is an indicator of BD in MM; its metabolism and function in MM should be clarified.


International Journal of Hematology | 2005

The Maturation of Myeloma Cells Correlates with Sensitivity to Chemotherapeutic Agents

Yoshiaki Kuroda; Akira Sakai; Yoshiko Okikawa; Shoso Munemasa; Yuta Katayama; Hideo Hyodo; Jun Imagawa; Yasuo Takimoto; Hajime Okita; Megu Ohtaki; Akiro Kimura

We analyzed both morphologic and phenotypic findings of myeloma cells before and after chemotherapy in 21 patients with multiple myeloma. The morphologic analysis was based on the Greipp classification, and phenotypic analysis was performed by 3-color flow cytometry using the CD38 plasma gating method (Marrow plasma 38). Results with flow cytometry using a combination of MPC1, CD49e, and CD45 supported the morphologic findings for the myeloma cells. Treatment with 3 or 4 cycles of VAD (vincristine, doxorubicin, and dexamethasone) therapy was effective in reducing the total numbers of myeloma cells, but the proportion of immature myeloma cells increased after this treatment. However, the immature myeloma cells were reduced by high-dose melphalan (HD-Mel) therapy followed by autologous stem cell transplantation (ASCT). High-dose cyclophosphamide treatment for stem cell harvesting did not show an effect on the residual immature myeloma cells after VAD treatment. In addition, thalidomide was not effective in reducing the numbers of immature myeloma cells. These results suggest that VAD (3 or 4 cycles) therapy plus HD-Mel followed by ASCT is a reasonable treatment for multiple myeloma and that Marrow plasma 38 analysis is a useful method for monitoring the response of multiple myeloma to chemotherapy.


International Journal of Oncology | 2008

Osteoprogenitor differentiation is not affected by immunomodulatory thalidomide analogs but is promoted by low bortezomib concentration, while both agents suppress osteoclast differentiation.

Shoso Munemasa; Akira Sakai; Yoshiaki Kuroda; Yoshiko Okikawa; Yuta Katayama; Hideki Asaoku; Tadahiko Kubo; Shoji Shimose; Akiro Kimura


International Journal of Oncology | 1992

Ectopic cyclin D1 overexpression increases chemosensitivity but not cell proliferation in multiple myeloma.

Yoshiaki Kuroda; Akira Sakai; Naohiro Tsuyama; Yuta Katayama; Shoso Munemasa; Hideki Asaoku; Yoshiko Okikawa; Nanae Nakaju; Mami Mizuno; Katsunari Ogawa; Takashi Nishisaka; Hirotaka Matsui; Hideo Tanaka; Akiro Kimura


Blood | 2007

Immunomodulatory Thalidomide Analogs Do Not Affect Osteoprogenitor Differentiation and Low Concentration of Bortezomib Promotes It, While Both Agents Suppress Osteoclast Differentiation.

Shoso Munemasa; Akira Sakai; Yoshiaki Kuroda; Yoshiko Okikawa; Yuta Katayama; Hideki Asaoku; Tadahiko Kubo; Shoji Shimose; Akiro Kimura


Blood | 2007

Cyclin D1 Overexpression Increases Chemosensitivity Via Prolonged S-Phase and TRAIL Signal in Myeloma Cell.

Yoshiaki Kuroda; Akira Sakai; Naohiro Tsuyama; Yuta Katayama; Shoso Munemasa; Yoshiko Okikawa; Hideki Asaoku; Nanae Nakaju; Mami Mizuno; Takashi Nishizaka; Katsunari Ogawa; Hideo Tanaka; Akiro Kimura


Blood | 2006

Connective Tissue Growth Factor (CTGF) Is an Indicator of Bone Involvement in Multiple Myeloma.

Shoso Munemasa; Akira Sakai; Yoshiaki Kuroda; Yoshiko Okikawa; Yuta Katayama; Hideki Asaoku; Tadahiko Kubo; Noelynn Oliver; Akiro Kimura


Blood | 2006

Cyclin D1 Overexpression Increases Chemosensitivity Via the Induction of Bim in Myeloma Cells.

Yoshiaki Kuroda; Akira Sakai; Naohiro Tsuyama; Shoso Munemasa; Nanae Nakaju; Mami Mizuno; Yoshiko Okikawa; Yuta Katayama; Akiro Kimura


Blood | 2005

Induction of Cyclin D1 Gene in Myeloma Cells Down-Regulates the Expression of Cyclin D2.

Yoshiaki Kuroda; Akira Sakai; Naohiro Tsuyama; Mami Mizuno; Nanae Nakaju; Shoso Munemasa; Yoshiko Okikawa; Yuta Katayama; Akiro Kimura


Blood | 2004

The Reason Why High-Dose Melphalan Followed by Autologous Stem-Cell Transplantation Produces Good Response in Multiple Myeloma.

Yoshiaki Kuroda; Akira Sakai; Yoshiko Okikawa; Shoso Munemasa; Yuta Katayama; Yasuo Takimoto; Hajime Okita; Akiro Kimura

Collaboration


Dive into the Shoso Munemasa's collaboration.

Top Co-Authors

Avatar

Akira Sakai

Fukushima Medical University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge